Hepatitis B virus mutations associated with antiviral therapy
β Scribed by A. Bartholomeusz; S. Locarnini
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 77 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Hepatitis B virus (HBV) core promoter mutations have been implicated in the pathogenesis of fulminant hepatitis B. Due to the limited availability of primary human hepatocytes, the functional characterization of HBV mutants has been performed predominantly in transformed cells, which may not represe
Typically, hepatitis B virus (HBV) decays in patients under therapy in a biphasic manner. However, more complex decay profiles of HBV DNA (e.g., flat partial response, triphasic, and stepwise), for which we have no clear understanding, have also been observed in some treated patients. We recently in
Several mutations (V521L, P525L, L528M, T532S, and V555I) in the gene for hepatitis B virus (HBV) polymerase have been identified in HBV isolated from patients that displayed break-through viremia during famciclovir treatment. To determine whether these mutations cause phenotypic resistance to famci